Table 2.

Placebo-subtracted change in metabolic parameters in individuals with and without diabetes receiving empagliflozin

	Patients with T2D	Individuals without diabetes	P
UGE, g/h	+2.55 ± 0.41	+1.59 ± 0.15	NS
Body weight, kg	−1.79 ± 0.25	−3.19 ± 0.48	NS
Percentage of body weight	−1.8	−3.4
FPG, mg/dL	−31 ± 6	−3 ± 2	<0.0001
HbA1c, %	−0.84 ± 0.2	−0.24 ± 0.10	<0.0001
EGP, mg/kg ⋅ min	+0.57 ± 0.12	+0.38 ± 0.10	NS
Liver fat content, %	−3.75 ± 0.79	−2.73 ± 0.73	NS
ALT, IU	−11 ± 3	−5 ± 4	NS
AST, IU	−5 ± 2	−2 ± 2	NS
Matsuda index	+2.4 ± 0.2	+2.3 ± 0.2	NS
Hematocrit, %	+1.9 ± 0.5	+1.3 ± 0.6	NS